[CLAIMS]

[Claim 1]

An aqueous suspension liquid formulation comprising powder of(E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, wherein the powder has been subjected to a heat treatment,
wherein the heat treatment is a treatment in a sterilization step, the heat treatment comprises a heat treatment at about 150°C to about 170°C.

[Claim 2]

The aqueous suspension liquid formulation according to claim 1, further comprising a nonionic surfactant.

[Claim 3]

The aqueous suspension liquid formulation according to claim 1 or 2, wherein the heat treatment is performed for about 30 minutes to about 5 hours.

[Claim 4]

An aqueous suspension liquid formulation comprising powder of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof and a nonionic surfactant, wherein the powder has been subjected to a heat treatment,
wherein the heat treatment is a treatment in a sterilization step, the heat treatment comprises a heat treatment at about 150°C to about 170°C,
wherein the heat treatment is performed for about 30 minutes to about 5 hours.

[Claim 5]

The aqueous suspension liquid formulation according to claim 2 or 4, wherein the nonionic surfactant has a concentration of about 0.0001 w/v% to about 1 w/v% in the aqueous suspension liquid formulation.

[Claim 6]

The aqueous suspension liquid formulation according to claim 2 or 4, wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate, polyethylene glycol monostearate, and a polyoxyethylene hydrogenated castor oil.

[Claim 7]

The aqueous suspension liquid formulation according to claim 2 or 4, wherein the nonionic surfactant has a concentration of about 0.0001 w/v% to about 1 w/v% in the aqueous suspension liquid formulation,
wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate, polyethylene glycol monostearate, and a polyoxyethylene hydrogenated castor oil.

[Claim 8]

The aqueous suspension liquid formulation according to claim 1, 2 or 4, wherein the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof has a concentration of about 0.01 w/v% to about 5 w/v% in the aqueous suspension liquid formulation.

[Claim 9]

The aqueous suspension liquid formulation according to claim 1, 2 or 4, wherein the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8 tetrahydronaphthalen-1-yl)acetamide.

[Claim 10]

An aqueous suspension liquid formulation, comprising

powder of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7 hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a

pharmaceutically acceptable salt or solvate thereof, wherein the powder has been subjected to a heat treatment, the (E)-2-(7 trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8 tetrahydronaphthalen-1-yl)acetamide or the pharmaceutically acceptable salt or solvate thereof having improved redispersibility in the aqueous suspension liquid formulation, wherein the heat treatment is a treatment in a sterilization step, the heat treatment comprises a heat treatment at about 150°C to about 170°C.

[Claim 11]

The aqueous suspension liquid formulation according to claim 10, wherein the improved redispersibility is a property of redispersing suspended particles in less than about 35 shakes as evaluated by a shaking operation.

[Claim 12]

The aqueous suspension liquid formulation according to claim 10 or 11, wherein the improved redispersibility is a property of redispersing suspended particles in less than about 50 inversions as evaluated by an inversion operation.

[Claim 13]

An aqueous suspension liquid formulation, comprising

powder of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or the pharmaceutically acceptable salt or solvate thereof having an average particle size (D50) of about 1 μm to about 10 μm in the aqueous suspension liquid formulation, wherein the powder has been subjected to a heat treatment, wherein the heat treatment is a treatment in a sterilization step, the heat treatment comprises a heat treatment at about 150°C to about 170°C.

[Claim 14]

A method for producing an aqueous suspension liquid formulation, the method comprising:

heat-treating powder of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, wherein the powder has been subjected to a heat treatment, wherein the heat treatment is a treatment in a sterilization step, the heat treatment comprises a heat treatment at about 150°C to about 170°C; and

mixing the thus-heat-treated powder with a solvent.